Chronic kidney disease (CKD) is defined as an abnormality of kidney structure or function present for longer than 3 months. CKD can occur as a result of heterogeneous disorders affecting the kidney. In the United States, an estimated 13.6% of adults have CKD. Notably, adjusted mortality rates are higher for patients with CKD than those without, and rates increase with CKD stage. The purpose of this algorithm is to enable accurate CKD diagnosis and staging based on EHR data.
Denny’s Group at Vandy
Note: Attached documents contain full case definition and two different control definitions. One is for controls with 2 years of follow up, the other for controls with 1 year of follow up. All available controls with 2 years of follow up were used in Vanderbilt's study. The control population was supplemented by controls with only 1 year of follow up. At the time of study, many of the available controls had experienced their qualifying events somewhat recently and 2 years had not yet passed for full follow up.
Clostridium difficile, also known as "C. diff," is a species of bacteria that causes severe diarrhea and other intestinal disease when competing bacteria in the gut have been wiped out by antibiotics (see Wikipedia entry). In rare cases a C. diff infection can progress to toxic megacolon which can be life-threatening. In a very small percentage of the adult population C. difficile bacteria naturally reside in the gut. Other people accidentally ingest spores of the bacteria while patients in a hospital or nursing home.
Fibromyalgia has been estimated to affect 12-17% of rheumatoid arthritis patients (1, 2).
This algorithm was created to identify fibromyalgia patients in a population of rheumatoid arthritis patients. The gold standard used for diagnosis of fibromyalgia was that the treating rheumatologist made a clinical diagnosis of fibromyalgia. Rheumatoid arthritis patients were identified by using a previously validated algorithm (3).
Algorithm included the following conditions:
Non-alcoholic fatty liver disease (NAFLD)
This algorithm predicts those who are going to be exposed to warfarin, simvastatin, or clopidogrel as three medications that have known pharmacogenomic influences. This algorithm was used to select individuals for the Vanderbilt PREDICT (Pharmacogenomic Resource for Enhanced Decisions in Care & Treatment) program, which prospectively tests individuals at risk of needing medications whose efficacy is effected by genetic variants.
For more information on PREDICT, see http://mydruggenome.org.
Phenotyping algorithm for the identification of patients with type 1 or type 2 diabetes mellitus (DM) preoperatively using routinely available clinical data from electronic